Real-World Data Show Trastuzumab Deruxtecan Extends Survival in HER2-Low Metastatic Breast Cancer
A real-world cohort of 126 Chinese patients shows trastuzumab deruxtecan delivers a median 9.1 months of progression-free survival in HER2-low ...
A real-world cohort of 126 Chinese patients shows trastuzumab deruxtecan delivers a median 9.1 months of progression-free survival in HER2-low ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine